On Sept 28, 2020, the US Food and Drug Administration (FDA) approved Pfizer’s targeted synthetic drug tofacitinib (Xeljanz) for the treatment of polyarticular juvenile idiopathic arthritis. The drug, a Janus kinase (JAK) inhibitor, had previously been approved for use in adults with rheumatoid arthritis, but is the first in its class to be approved to […]